In the present study, we described the clinical characteristics, risk factors and constructed a model of the outcome of NSCLC patients treated with anti-PD-1/PD-L1 plus bevacizumab to provide a theoretical basis for better prognosis. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.